'Total amateur hour'—Cramer on communication from AstraZeneca regarding trial pause

The participant who triggered a global shutdown of AstraZeneca’s Phase 3 Covid-19 vaccine trials was a woman in the United Kingdom who experienced neurological symptoms consistent with a rare but serious spinal inflammatory disorder called transverse myelitis, the drug maker’s chief executive, Pascal Soriot, said during a private conference call with investors on Wednesday morning. CNBC's Meg Tirrell discusses the latest vaccine news with CNBC's Jim Cramer.
Thu, Sep 10 202010:07 AM EDT